As of 2025-09-17, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is 0.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is -8.85 mil USD. CHRS's TTM EBITDA according to its financial statements is -126.89 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 16.6x | 14.4x |
| Forward P/E multiples | 12.8x - 19.1x | 15.8x |
| Fair Price | (10.97) - 2.75 | (5.88) |
| Upside | -906.3% - 102.4% | -532.5% |
| Date | EV/EBITDA |
| 2025-09-16 | 0.07 |
| 2025-09-15 | 0.15 |
| 2025-09-12 | 0.13 |
| 2025-09-11 | 0.10 |
| 2025-09-10 | 0.12 |
| 2025-09-09 | 0.08 |
| 2025-09-08 | 0.06 |
| 2025-09-05 | 0.13 |
| 2025-09-04 | 0.12 |
| 2025-09-03 | 0.16 |
| 2025-09-02 | 0.23 |
| 2025-08-29 | 0.25 |
| 2025-08-28 | 0.23 |
| 2025-08-27 | 0.27 |
| 2025-08-26 | 0.28 |
| 2025-08-25 | 0.24 |
| 2025-08-22 | 0.19 |
| 2025-08-21 | 0.28 |
| 2025-08-20 | 0.34 |
| 2025-08-19 | 0.34 |
| 2025-08-18 | 0.34 |
| 2025-08-15 | 0.35 |
| 2025-08-14 | 0.38 |
| 2025-08-13 | 0.40 |
| 2025-08-12 | 0.48 |
| 2025-08-11 | 0.51 |
| 2025-08-08 | 0.56 |
| 2025-08-07 | 0.51 |
| 2025-08-06 | 0.48 |
| 2025-08-05 | 0.48 |
| 2025-08-04 | 0.52 |
| 2025-08-01 | 0.51 |
| 2025-07-31 | 0.45 |
| 2025-07-30 | 0.43 |
| 2025-07-29 | 0.39 |
| 2025-07-28 | 0.34 |
| 2025-07-25 | 0.36 |
| 2025-07-24 | 0.38 |
| 2025-07-23 | 0.42 |
| 2025-07-22 | 0.47 |
| 2025-07-21 | 0.50 |
| 2025-07-18 | 0.51 |
| 2025-07-17 | 0.49 |
| 2025-07-16 | 0.49 |
| 2025-07-15 | 0.54 |
| 2025-07-14 | 0.45 |
| 2025-07-11 | 0.51 |
| 2025-07-10 | 0.52 |
| 2025-07-09 | 0.52 |
| 2025-07-08 | 0.57 |